GlaxoSmithKline PLC Company Profile (NYSE:GSK)

About GlaxoSmithKline PLC (NYSE:GSK)

GlaxoSmithKline PLC logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:GSK
  • CUSIP: N/A
  • Web:
  • Market Cap: $99.35 billion
  • Outstanding Shares: 2,444,000,000
Average Prices:
  • 50 Day Moving Avg: $39.76
  • 200 Day Moving Avg: $41.75
  • 52 Week Range: $37.20 - $44.54
  • Trailing P/E Ratio: 39.40
  • Foreward P/E Ratio: 14.16
  • P/E Growth: 1.22
Sales & Book Value:
  • Annual Revenue: $39.37 billion
  • Price / Sales: 2.52
  • Book Value: $0.44 per share
  • Price / Book: 92.39
  • Annual Dividend: $1.97
  • Dividend Yield: 4.9%
  • EBIDTA: $10.76 billion
  • Net Margins: 6.48%
  • Return on Equity: 114.93%
  • Return on Assets: 9.25%
  • Debt-to-Equity Ratio: 2.77%
  • Current Ratio: 0.57%
  • Quick Ratio: 0.37%
  • Average Volume: 2.71 million shs.
  • Beta: 1.03
  • Short Ratio: 1.71

Frequently Asked Questions for GlaxoSmithKline PLC (NYSE:GSK)

What is GlaxoSmithKline PLC's stock symbol?

GlaxoSmithKline PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline PLC pay dividends? What is the dividend yield for GlaxoSmithKline PLC?

GlaxoSmithKline PLC declared a quarterly dividend on Wednesday, July 26th. Stockholders of record on Friday, August 11th will be given a dividend of $0.491 per share on Thursday, October 12th. This represents a $1.96 annualized dividend and a dividend yield of 4.83%. The ex-dividend date is Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC's previous quarterly dividend of $0.46. View GlaxoSmithKline PLC's Dividend History.

How were GlaxoSmithKline PLC's earnings last quarter?

GlaxoSmithKline PLC (NYSE:GSK) released its quarterly earnings results on Wednesday, July, 26th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. View GlaxoSmithKline PLC's Earnings History.

When will GlaxoSmithKline PLC make its next earnings announcement?

GlaxoSmithKline PLC is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for GlaxoSmithKline PLC.

Where is GlaxoSmithKline PLC's stock going? Where will GlaxoSmithKline PLC's stock price be in 2017?

15 brokers have issued 12-month price targets for GlaxoSmithKline PLC's stock. Their forecasts range from $37.00 to $50.00. On average, they expect GlaxoSmithKline PLC's stock price to reach $43.50 in the next year. View Analyst Ratings for GlaxoSmithKline PLC.

Who are some of GlaxoSmithKline PLC's key competitors?

Who are GlaxoSmithKline PLC's key executives?

GlaxoSmithKline PLC's management team includes the folowing people:

  • Emma Walmsley, Chief Executive Officer - Designate, Executive Director
  • Simon Dingemans, Chief Financial Officer, Executive Director
  • Patrick Vallance, President - Pharmaceuticals R&D, Executive Director
  • Roger Connor, President - Global Manufacturing & Supply
  • Abbas Hussain, President - Global Pharmaceuticals
  • Shah Abbas Hussain, President - Global Pharmaceuticals
  • Luke Miels, President - Global Pharmaceuticals
  • Daniel E Troy, Senior Vice President, General Counsel
  • Claire Thomas, Senior Vice President - Human Resources
  • Nick Hirons, Senior Vice President – Global Ethics and Compliance

Who owns GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (1.02%), Fisher Asset Management LLC (0.51%), State Street Corp (0.42%), Renaissance Technologies LLC (0.38%), Hotchkis & Wiley Capital Management LLC (0.32%) and Bank of New York Mellon Corp (0.24%). View Institutional Ownership Trends for GlaxoSmithKline PLC.

Who sold GlaxoSmithKline PLC stock? Who is selling GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Ameriprise Financial Inc., Miller Howard Investments Inc. NY, Schafer Cullen Capital Management Inc., Equity Investment Corp Acquisition Inc, State Street Corp, JPMorgan Chase & Co. and Paulson & CO. Inc.. View Insider Buying and Selling for GlaxoSmithKline PLC.

Who bought GlaxoSmithKline PLC stock? Who is buying GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, Federated Investors Inc. PA, Marshall Wace North America L.P., Fisher Asset Management LLC, Sphera Funds Management LTD., Hotchkis & Wiley Capital Management LLC and Parametric Portfolio Associates LLC. View Insider Buying and Selling for GlaxoSmithKline PLC.

How do I buy GlaxoSmithKline PLC stock?

Shares of GlaxoSmithKline PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline PLC's stock price today?

One share of GlaxoSmithKline PLC stock can currently be purchased for approximately $40.65.

MarketBeat Community Rating for GlaxoSmithKline PLC (NYSE GSK)
Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  637 (Vote Underperform)
Total Votes:  950
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GlaxoSmithKline PLC (NYSE:GSK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 6 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $43.50 (7.01% upside)

Analysts' Ratings History for GlaxoSmithKline PLC (NYSE:GSK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017J P Morgan Chase & CoReiterated RatingNeutralLowView Rating Details
9/8/2017Morgan StanleyDowngradeEqual Weight -> UnderweightLowView Rating Details
8/31/2017ArgusReiterated RatingBuy$50.00LowView Rating Details
7/27/2017Citigroup Inc.Reiterated RatingNeutralLowView Rating Details
5/26/2017Berenberg BankUpgradeHold -> BuyLowView Rating Details
4/6/2017BNP ParibasLower Price Target$37.00LowView Rating Details
4/5/2017Exane BNP ParibasUpgradeUnderperform -> NeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/9/2017Kepler Capital MarketsInitiated CoverageReduce -> ReduceLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageEqual WeightN/AView Rating Details
2/19/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
2/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
12/27/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyN/AView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/AView Rating Details
10/20/2016InvestecInitiated CoverageBuyN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/AView Rating Details
9/20/2016Bank of America CorporationReiterated RatingBuy$50.00N/AView Rating Details
9/12/2016HSBC Holdings plcReiterated RatingBuyN/AView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
5/26/2016Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyN/AView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldN/AView Rating Details
2/4/2016Sanford C. BernsteinBoost Price TargetMarket Perform$43.00 -> $45.00N/AView Rating Details
1/27/2016Bryan, Garnier & CoUpgradeNeutral -> BuyN/AView Rating Details
12/21/2015Leerink SwannReiterated RatingMarket Perform$48.00N/AView Rating Details
10/31/2015Societe GeneraleReiterated RatingSellN/AView Rating Details
10/20/2015Credit Suisse GroupUpgradeUnderperform -> NeutralN/AView Rating Details
(Data available from 9/26/2015 forward)


Earnings History for GlaxoSmithKline PLC (NYSE:GSK)
Earnings by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Earnings History by Quarter for GlaxoSmithKline PLC (NYSE GSK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.82N/AView Earnings Details
7/26/20176/30/2017$0.68$0.70$9.52 billion$9.36 billionViewN/AView Earnings Details
4/26/20173/31/2017$0.62$0.62$9.09 billion$9.23 billionViewN/AView Earnings Details
2/8/201712/31/2016$0.57$0.65$9.21 billion$9.43 billionViewListenView Earnings Details
10/26/2016Q316$0.77$0.83$8.92 billion$9.90 billionViewListenView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53$9.14 billion$9.02 billionViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48$8.55 billion$8.51 billionViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90$9.76 billion$9.12 billionViewListenView Earnings Details
7/23/2014Q114$0.71$0.65$10.13 billion$9.47 billionViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70$10.36 billion$9.44 billionViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)
2017 EPS Consensus Estimate: $2.88
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.59$0.63$0.61
Q2 20171$0.71$0.71$0.71
Q3 20171$0.81$0.81$0.81
Q4 20171$0.75$0.75$0.75
(Data provided by Zacks Investment Research)


Current Dividend Information for GlaxoSmithKline PLC (NYSE:GSK)
Next Dividend:10/12/2017
Annual Dividend:$1.97
Dividend Yield:4.85%
Dividend Growth:-3.10% (3 Year Average)
Payout Ratio:197.00% (Trailing 12 Months of Earnings)
68.64% (Based on This Year's Estimates)
68.64% (Based on Next Year's Estimates)
Dividend Payments by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Dividend History by Quarter for GlaxoSmithKline PLC (NYSE GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for GlaxoSmithKline PLC (NYSE:GSK)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 9.28%
Insider Trades by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Insider Trades by Quarter for GlaxoSmithKline PLC (NYSE:GSK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GlaxoSmithKline PLC (NYSE:GSK)
Latest Headlines for GlaxoSmithKline PLC (NYSE:GSK)
DateHeadline logoWhy I’d buy GlaxoSmithKline plc for its 5%+ dividend yield today - September 25 at 10:29 AM logoPharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update - September 22 at 11:30 AM logoJ P Morgan Chase & Co Reiterates Neutral Rating for GlaxoSmithKline PLC (GSK) - September 21 at 6:20 AM logoGlaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD ... - Nasdaq - September 20 at 5:21 AM logoGSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations - September 20 at 5:21 AM logoGSK's new triple lung drug beats other modern inhalers in study - September 20 at 5:21 AM logoGlaxoSmithKline's Trelegy Ellipta wins FDA OK - September 19 at 7:15 PM logo[$$] Andrew Witty jumps into biotech venture capital - September 19 at 7:15 PM logoGlaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD - September 19 at 7:15 PM logoFDA OKs Glaxo's inhaler, first one to combine 3 medicines - September 19 at 7:15 PM logoGlaxoSmithKline breathes easier as U.S. approves triple lung drug - September 19 at 4:49 AM logoGlaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU - Nasdaq - September 18 at 6:45 PM logoInteresting GSK Put And Call Options For May 2018 - Nasdaq - September 18 at 6:45 PM logoTrelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US - September 18 at 6:45 PM logoInnoviva (INVA) & GlaxoSmithKline Plc (GSK) Reports Positive Opinion from EMA CHMP for Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy - September 16 at 6:02 AM logoFrance's Neovacs takes on GSK and AstraZeneca in battle to treat lupus - September 15 at 7:54 PM logoGSK, Innoviva: Trelegy Ellipta Gets CHMP Positive Opinion In Europe For COPD - September 15 at 5:58 AM logoTrelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD - September 15 at 5:58 AM logoGSK's three-in-one inhaler gets positive opinion from EU agency - September 15 at 5:58 AM logoOne long-term growth stock I’d buy alongside GlaxoSmithKline plc - September 14 at 7:55 PM logoJ P Morgan Chase & Co Reiterates "Neutral" Rating for GlaxoSmithKline PLC (GSK) - September 14 at 6:36 AM logoGlaxo shingles vaccine gets FDA panel backing - MarketWatch - September 14 at 3:34 AM logoGlaxoSmithKline Plc : GSK-US: Dividend Analysis : August 11th, 2017 (record date) : By the numbers : September 12, 2017 - September 12 at 8:07 PM logo3 Dividend Superstars With Strong Growth Potential: GlaxoSmithKline, Pfizer, Sanofi - September 12 at 8:00 AM logoWhy GlaxoSmithKline plc is the only pharma stock I’d ever own - September 12 at 8:00 AM logoGSK Publishes Results Of Phase III Studies For Mepolizumab In COPD - September 12 at 8:00 AM logoWhen Should You Buy GlaxoSmithKline plc (LSE:GSK)? - September 12 at 8:00 AM logoInnoviva (INVA) & GlaxoSmithKline (GSK) Announce Positive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet - September 11 at 7:45 PM logoHow Merck’s Gardasil and Other Human Vaccines Performed in 2Q17 - September 11 at 7:45 PM logoPositive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet, and Presented at European Respiratory Congress - September 11 at 4:25 AM logoGlaxoSmithKline PLC (GSK) Cut to Weight at Morgan Stanley - September 8 at 12:02 PM logoGlaxoSmithKline Exercises Option For Adaptimmune Oncology Programme - September 7 at 7:27 PM logoAdaptimmune Therapeutics (ADAP) Gains as GlaxoSmithKline (GSK) Exercises Option on SPEAR T-cell Therapy Program - September 7 at 7:27 PM logoAdaptimmune: GSK Exercises Option Over NY-ESO SPEAR T-Cell Therapy Program - September 7 at 7:27 PM logoGermany’s Merck Puts Consumer Drugs Business on the Block - September 6 at 7:11 PM logoNarasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018 - September 6 at 3:23 AM logoPharma strategy: GlaxoSmithKline sets up first team for acquisitions in 93 years - September 4 at 3:22 PM logoNovartis Calls for the Doctor - September 4 at 3:22 PM logoKey FDA Regulatory Events to Watch Out for in Sep 2017 - September 4 at 3:22 PM logoKey FDA Regulatory Events to Watch Out for in Sep 2017 - September 4 at 3:22 PM logoGlaxoSmithKline PLC (GSK) Given Average Rating of "Hold" by Brokerages - September 2 at 6:30 PM logoPromacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017 - September 1 at 7:38 PM logoAnalyzing GlaxoSmithKline’s Global Pharmaceuticals Business - September 1 at 7:38 PM logoGlaxoSmithKline’s Vaccines Business in 2Q17 - September 1 at 7:38 PM logoChanges in GlaxoSmithKline’s Valuation after 2Q17 - August 31 at 7:08 PM logoGlaxoSmithKline Reported Revenue Growth in 2Q17 - August 31 at 7:08 PM logoHow Did GlaxoSmithKline’s Segments Perform in 2Q17? - August 31 at 7:08 PM logoWhy GlaxoSmithKline’s Pharmaceuticals Business Grew - August 31 at 7:08 PM logoGlaxoSmithKline's 5% Yield Carries Considerable Risk - August 31 at 7:08 PM logoArgus Reiterates "Buy" Rating for GlaxoSmithKline PLC (GSK) - August 31 at 6:20 PM



GlaxoSmithKline PLC (GSK) Chart for Tuesday, September, 26, 2017

This page was last updated on 9/26/2017 by Staff